Alzinova: Promising results from high-dose cohort - Redeye

Redeye leaves a comment following Alzinova’s announced study data form the high-dose phase Ib extension study (part A2) with its vaccine candidate ALZ-101. We are encouraged to learn that findings confirm that the higher dose maintains the same strong safety and tolerability profile observed at lower levels, suggesting that ALZ-101 is well-tolerated and safe, while eliciting a high immune response in patients.

Länk till analysen i sin helhet: https://www.redeye.se/research/1080397/alzinova-promising-results-from-high-dose-cohort?utm_source=finwire&utm_medium=RSS